Clinical Rheumatology

, Volume 8, Issue 2, pp 231–237

Marker antibodies in scleroderma and polymyositis: Clinical associations

Authors

  • D. J. De Rooij
    • Department of Rheumatology
  • L. B. A. Van De Putte
    • Department of Rheumatology
  • W. J. Habets
    • Department of RheumatologyUniversity Hospital Nijmegen
  • W. J. Van Venrooij
    • Department of BiochemistryUniversity of Nijmegen
Originals

DOI: 10.1007/BF02030079

Cite this article as:
De Rooij, D.J., Van De Putte, L.B.A., Habets, W.J. et al. Clin Rheumatol (1989) 8: 231. doi:10.1007/BF02030079

Summary

Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies.

Key words

Antinuclear AntibodiesImmunoblottingSclerodermaPolymyositis

Copyright information

© Springer-Verlag 1989